Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease
Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease